TruScreen widens 1H loss but expects Q4 growth on Chinese sales

TruScreen widens 1H loss but expects Q4 growth on Chinese sales
Sophie Boot
By Sophie Boot Dec. 14 (BusinessDesk) - NZAX-listed TruScreen posted a 30 percent drop in revenue and widened its loss in the first half on delays to Chinese approval for its cervical screening device. Revenue dropped to $225,900 in the six months ended Sept. 30, from $361,400 a year earlier, while the first-half loss widened to $1.77 million from $1.68 million in the previous first half.  The Auckland-based cervical cancer test developer said its commercial performance was hampered in the first half due to delays in gaining CFDA appro...